Sensing the cardiac environment: Exploiting cues for regeneration

Journal of Cardiovascular Translational Research

Volumn 4, Issue 5, 2011, Pages 616-630

  Pereira, Maria José Nunes ^a,c,d   Carvalho, Isabel Fidalgo ^b   Karp, Jeffrey M ^c,d   Ferreira, Lino S ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Biocant Biotechnology Innovation Center   (Portugal)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Biomaterial; Cardiac regeneration; On demand release; Paracrine factors; Stem cells

Indexed keywords

BIOMATERIAL; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEINASE; REACTIVE OXYGEN METABOLITE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

BIOSENSOR; BONE MARROW CELL; CELL FUNCTION; CELL THERAPY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG MECHANISM; HEART DISEASE; HEART FUNCTION; HEART INFARCTION; HUMAN; MESENCHYMAL STEM CELL; MESENCHYME CELL; MICROENVIRONMENT; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOLECULAR SENSOR; MONONUCLEAR CELL; MYOBLAST; MYOFIBROBLAST; NONHUMAN; PARACRINE SIGNALING; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; STEM CELL; TISSUE REGENERATION; UPREGULATION;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELL COMMUNICATION; CELLULAR MICROENVIRONMENT; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; REGENERATION; REGENERATIVE MEDICINE; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TIME FACTORS; TISSUE ENGINEERING;

EID: 81855221996     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-011-9299-6     Document Type: Review

References (143)

1. Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabe- Heider, F., Walsh, S., et al. (2009). Evidence for cardiomyocyte renewal in humans. Science, 324(5923), 98-102. doi:10.1126/ science.1164680.
2. Jessup, M., & Brozena, S. (2003). Medical progress: Heart failure. The New England Journal of Medicine, 348(20), 2007-2018. doi:10.1056/ NEJMra021498. (Pubitemid 36569990)
3. Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., et al. (2010). Executive summary: Heart Disease and Stroke Statistics-2010 Update. A report from the American Heart Association. Circulation, 121(7), 948-954. doi:10.1161/circulationaha.109.192666.
4. Zimmermann, W. H. (2009). Remuscularizing failing hearts with tissue engineered myocardium. Antioxidants & Redox Signaling, 11(8), 2011-2023. doi:10.1089/ars.2009.2467.
5. Laflamme, M. A., & Murry, C. E. (2005). Regenerating the heart. Nature Biotechnology, 23(7), 845-856. doi:10.1038/ nbt1117. (Pubitemid 43093128)
6. Segers, V. F. M., & Lee, R. T. (2010). Protein therapeutics for cardiac regeneration after myocardial infarction. Journal of Cardiovascular Translational Research, 3(5), 469-477. doi:10.1007/s12265-010-9207-5.
7. Dimmeler, S., Zeiher, A. M., & Schneider, M. D. (2005). Unchain my heart: The scientific foundations of cardiac repair. The Journal of Clinical Investigation, 115(3), 572-583. doi:10.1172/jci200524283. (Pubitemid 40322227)
8. Alexander, J. M., & Bruneau, B. G. (2010). Lessons for cardiac regeneration and repair through development. Trends in Molecular Medicine, 16(9), 426-434. doi:10.1016/j.molmed.2010.06.003.
9. Vandervelde, S., van Luyn, M. J. A., Tio, R. A., & Harmsen, M. C. (2005). Signaling factors in stem cell-mediated repair of infarcted myocardium. Journal of Molecular and Cellular Cardiology, 39(2), 363-376. doi:10.1016/j.yjmcc.2005.05.012. (Pubitemid 40995026)
10. Eaton, L. W., Weiss, J. L., Bulkley, B. H., Garrison, J. B., & Weisfeldt, M. L. (1979). Regional cardiac dilatation after acute myocardial-infarction - recognitior by 2-dimensional echocardiography. The New England Journal of Medicine, 300(2), 57-62. doi:10.1056/NEJM197905173002014. (Pubitemid 9104309)
11. Jugdutt, B. I. (2003). Ventricular remodeling after infarction and the extracellular collagen matrix - When is enough enough? Circulation, 108(11), 1395-1403. doi:10.1161/01.cir.00000 85658.98621.49. (Pubitemid 37174420)
12. Ingber, D. E. (2002). Mechanical signalling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. CircRes, 91(10), 877-887. doi:10.1161/01.res. 0000039537.73816.e5. (Pubitemid 35373587)
13. Dobaczewski, M., Gonzalez-Quesada, C., & Frangogiannis, N. G. (2009). The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. Journal of Molecular and Cellular Cardiology, 48(3), 504-511. doi:10.1016/ j.yjmcc.2009.07.015.
14. Peterson, J. T., Li, H., Dillon, L., & Bryant, J. W. (2000). Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovascular Research, 46(2), 307-315. doi:10.1016/S0008-6363(00)00029-8. (Pubitemid 30204603)
15. Frangogiannis, N. G., Smith, C. W., & Entman, M. L. (2002). The inflammatory response in myocardial infarction. Cardiovascular Research, 53(1), 31-47. doi:10.1016/S0008-6363(01)00434-5. (Pubitemid 34020764)
16. Yellon, D. M., & Hausenloy, D. J. (2007). Mechanisms of disease: Myocardial reperfusion injury. The New England Journal of Medicine, 357(11), 1121-1135. doi:10.1056/NEJMra071667. (Pubitemid 47443217)
17. Murry, C. E., Jennings, R. B., & Reimer, K. A. (1986). Preconditioning with ischemia - a delay of lethal cell injury in ischemic myocardium. Circulation, 74(5), 1124-1136. (Pubitemid 17174962)
18. Lebuffe, G., Schumacker, P. T., Shao, Z. H., Anderson, T., Iwase, H., & Vanden Hoek, T. L. (2003). ROS and NO trigger early preconditioning: Relationship to mitochondrial K-ATP channel. Am J Physiol-Heart Circul Physiol, 284(1), H299-H308. doi:10.1152/ajpheart.00706.2002. (Pubitemid 36076298)
19. Garlid, K. D., Dos Santos, P., Xie, Z. J., Costa, A. D. T., & Paucek, P. (2003). Mitochondrial potassium transport: The role of the mitochondrial ATP-sensitive K+channel in cardiac function and cardioprotection. Biochim Biophys Acta-Bioenerg, 1606(1-3), 1-21. doi:10.1016/s0005-2728(03)00109-9. (Pubitemid 37267867)
20. Mukherjee, R., Mingoia, J. T., Bruce, J. A., Austin, J. S., Stroud, R. E., Escobar, G. P., et al. (2006). Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol-Heart Circul Physiol, 291(5), H2216-H2228. doi:10.1152/ajpheart.01343.2005.
21. Vanhoutte, D., Schellings, M., Pinto, Y., & Heymans, S. (2006). Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window. Cardiovascular Research, 69(3), 604-613. doi:10.1016/j.cardiores. 2005.10.002. (Pubitemid 43139724)
22. Webb, C. S., Bonnema, D. D., Ahmed, S. H., Leonardi, A. H., McClure, C. D., Clark, L. L., et al. (2006). Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction - Relation to left ventricular remodeling. Circulation, 114(10), 1020-1027. doi:10.1161/circulationaha.105. 600353. (Pubitemid 44358878)
23. Matsumura, S., Iwanaga, S., Mochizuki, S., Okamoto, H., Ogawa, S., & Okada, Y. (2005). Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. The Journal of Clinical Investigation, 115(3), 599-609. doi:10.1172/jci200522304. (Pubitemid 40322234)
24. Olivetti, G., Capasso, J. M., Sonnenblick, E. H., & Anversa, P. (1990). Side-to-side slippage of myocites participated in ventricular wall remodelling acutely after myocardial-infarction rats. CircRes, 67(1), 23-34. (Pubitemid 20223724)
25. Askari, A. T., Unzek, S., Popovic, Z. B., Goldman, C. K., Forudi, F., Kiedrowski, M., et al. (2003). Effect of stromal-cellderived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet, 362(9385), 697-703. doi:10.1016/S0140-6736(03)14232-8. (Pubitemid 37101067)
26. Abbott, J. D., Huang, Y., Liu, D., Hickey, R., Krause, D. S., & Giordano, F. J. (2004). Stromal cell-derived factor-1 alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation, 110(21), 3300-3305. doi:10.1161/01.cir.0000147780.30124.cf. (Pubitemid 39557491)
27. Kucia, M., Dawn, B., Hunt, G., Guo, Y. R., Wysoczynski, M., Majka, M., et al. (2004). Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. CircRes, 95(12), 1191-1199. doi:10.1161/01.RES.0000150856.47324.5b. (Pubitemid 39648210)
28. Ankrum, J., & Karp, J. M. (2010). Mesenchymal stem cell therapy: Two steps forward, one step back. Trends in Molecular Medicine, 16(5), 203-209. doi:10.1016/j.molmed. 2010.02.005.
29. Yang, Z. Q., Zingarelli, B., & Szabo, C. (2000). Crucial role of endogenous interleukin-10 production in myocardial ischemia/ reperfusion injury. Circulation, 101(9), 1019-1026. (Pubitemid 30131705)
30. Burchfield, J. S., Iwasaki, M., Koyanagi, M., Urbich, C., Rosenthal, N., Zeiher, A. M., et al. (2008). Interleukin-10 from transplanted bone marrow mononuclear cells contributes to cardiac protection after myocardial infarction. CircRes, 103(2), 203-211. doi:10.1161/circresaha.108.178475.
31. Tziakas, D. N., Chalikias, G. K., Hatzinikolaou, H. I., Parissis, J. T., Papadopoulos, E. D., Trypsianis, G. A., et al. (2003). Antiinflammatory cytokine profile in acute coronary syndromes: Behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines. International Journal of Cardiology, 92(2-3), 169-175. doi:10.1016/s0167-5273(03) 00084-6. (Pubitemid 37509978)
32. Krishnamurthy, P., Lambers, E., Verma, S., Thorne, T., Qin, G. J., Losordo, D. W., et al. (2010). Myocardial knockdown of mRNAstabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice. The FASEB Journal, 24(7), 2484-2494. doi:10.1096/fj.09-149815.
33. Bujak, M., & Frangogiannis, N. G. (2007). The role of TGFbeta signaling in myocardial infarction and cardiac remodeling. Cardiovascular Research, 74(2), 184-195. doi:10.1016/j. cardiores.2006.10.002. (Pubitemid 46517504)
34. Dewald, O., Zymek, P., Winkelmann, K., Koerting, A., Ren, G. F., Abou-Khamis, T., et al. (2005). CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. CircRes, 96(8), 881-889. doi:10.1161/01. RES.0000163017.13772.3a. (Pubitemid 40604972)
35. Eghbali, M., Tomek, R., Woods, C., & Bhambi, B. (1991). Cardiac fibroblast are predisposed to convert into myocyte phenotype - specific effect of transforming growth-factor-beta. Proceedings of the National Academy of Sciences of the United States of America, 88(3), 795-799. doi:10.1073/pnas.88.3. 795. (Pubitemid 21916110)
36. Cleutjens, J. P. M., Verluyten, M. J. A., Smits, J. F. M., & Daemen, M. (1995). Collagen remodeling after myocardialinfarction in the rat-heart. Am J Pathol, 147(2), 325-338.
37. van den Borne, S. W. M., Diez, J., Blankesteijn, W. M., Verjans, J., Hofstra, L., & Narula, J. (2009). Myocardial remodeling after infarction: The role of myofibroblasts. Nat Rev Cardiol, 7(1), 30-37. doi:10.1038/nrcardio. 2009.199.
38. McCormick, R. J., Musch, T. I., Bergman, B. C., & Thomas, D. P. (1994). Regional differences in LV collagen accumulation and mature cross-linking after myocardial-infarction in rats. Am J Physiol, 266(1), H354-H359. (Pubitemid 24051527)
39. Gnecchi, M., Zhang, Z. P., Ni, A. G.,& Dzau, V. J. (2008). Paracrine mechanisms in adult stem cell signaling and therapy. Circulation Research, 103(11), 1204-1219. doi:10.1161/circresaha.108. 176826.
40. Hwang, H., & Kloner, R. A. (2010). Improving regenerating potential of the heart after myocardial infarction: Factor-based approach. Life Sciences, 86(13-14), 461-472. doi:10.1016/j. lfs.2010.01.004.
41. Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116(2), 281-297. doi:10.1016/ S0092-8674(04)00045-5.
42. Lai, R. C., Arslan, F., Lee, M.M., Sze, N. S. K., Choo, A., Chen, T. S., et al. (2010). Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Research, 4(3), 214-222. doi:10.1016/j.scr.2009.12.003.
43. Chen, T. S., Lai, R. C., Lee, M. M., Choo, A. B. H., Lee, C. N., & Lim, S. K. (2010). Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Research, 38(1), 215-224. doi:10.1093/nar/gkp857.
44. Hu SJ, Huang M, Li ZJ, Jia FJ, Ghosh ZM, Lijkwan MA, Fasanaro P, Sun N,Wang X, Li FM, Robbins RC,Wu JCMicroRNA-210 as a Novel Therapy for Treatment of Ischemic Heart Disease. Circulation 122 (11):S124-S131. doi:10.1161/ circulationaha.109.928424
45. van der Bogt, K. E. A., Sheikh, A. Y., Schrepfer, S., Hoyt, G., Cao, F., Ransohoff, K. J., et al. (2008). Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation, 118(14), S121-U166. doi:10.1161/circulationaha.107.759480.
46. Arminan, A., Gandia, C., Garcia-Verdugo, J. M., Lledo, E., Trigueros, C., Ruiz-Sauri, A., et al. (2009). Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction. Journal of the American College of Cardiology, 55(20), 2244-2253. doi:10.1016/j. jacc.2009.08.092.
47. Kamihata, H., Matsubara, H., Nishiue, T., Fujiyama, S., Tsutsumi, Y., Ozono, R., et al. (2001). Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation, 104 (9), 1046-1052. doi:10.1161/hc3501.093817. (Pubitemid 32803883)
48. Kraehenbuehl, T. P., Ferreira, L. S., Hayward, A. M., Nahrendorf, M., van der Vlies, A. J., Vasile, E., et al. (2010). Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. Biomaterials, 32 (4), 1102-1109. doi:10.1016/j.biomaterials.2010.10. 005.
49. Chimenti, I., Smith, R. R., Li, T. S., Gerstenblith, G., Messina, E., Giacomello, A., et al. (2010). Relative roles of direct regeneration versus paracrine effects of human cardiospherederived cells transplanted into infarcted mice. CircRes, 106(5), 971-U304. doi:10.1161/circresaha.109.210682.
50. Suzuki K, Murtuza B, Beauchamp JR, Brand NJ, Barton PJR, Varela-Carver A, Fukushima S, Coppen SR, Partridge TA, Yacoub MH (2004) Role of interleukin-1 beta in acute inflammation and graft death after cell transplantation to the heart. Circulation 110 (11):II219-II224. doi:10.1161/01.cir.0000138388.55416.06 (Pubitemid 39263726)
51. Shintani, Y., Fukushima, S., Varela-Carver, A., Lee, J., Coppen, S. R., Takahashi, K., et al. (2009). Donor cell-type specific paracrine effects of cell transplantation for post-infarction heart failure. Journal of Molecular and Cellular Cardiology, 47(2), 288-295. doi:10.1016/j.yjmcc.2009.05.009.
52. Mirotsou, M., Zhang, Z. Y., Deb, A., Zhang, L. N., Gnecchi, M., Noiseux, N., et al. (2007). Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proceedings of the National Academy of Sciences of the United States of America, 104(5), 1643-1648. doi:10.1073/pnas.0610024104. (Pubitemid 46214644)
53. Wang, M. J., Tan, J. N., Wang, Y., Meldrum, K. K., Dinarello, C. A., & Meldrum, D. R. (2009). IL-18 binding protein-expressing mesenchymal stem cells improve myocardial protection after ischemia or infarction. Proceedings of the National Academy of Sciences of the United States of America, 106(41), 17499-17504. doi:10.1073/pnas.0908924106.
54. Li, W. Z., Ma, N., Ong, L. L., Nesselmann, C., Klopsch, C., Ladilov, Y., et al. (2007). Bc1-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells, 25(8), 2118-2127. doi:10.1634/stemcells.2006-0771. (Pubitemid 47258191)
55. Wang, X. H., Zhao, T. M., Huang, W., Wang, T., Qian, J., Xu, M. F., et al. (2009). Hsp20-Engineered mesenchymal stem cells Are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells, 27(12), 3021-3031. doi:10.1002/stem.230.
56. Huang, J., Zhang, Z. P., Guo, J. A., Ni, A. G., Deb, A., Zhang, L. N., et al. (2010). Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. CircRes, 106(11), 1753-U1189. doi:10.1161/circresaha.109. 196030.
57. Pouyssegur, J., Dayan, F., & Mazure, N. M. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 441(7092), 437-443. doi:10.1038/nature04871. (Pubitemid 44050138)
58. Chen, L. W., Tredget, E. E., Wu, P. Y. G., & Wu, Y. J. (2008). Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PloS One, 3(4), 12. doi:10.1371/journal.pone.0001886, e1886.
59. Wang, M. J., Crisostomo, P. R., Herring, C., Meldrum, K. K., & Meldrum, D. R. (2006). Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 291(4), R880-R884. doi:10.1152/ ajpregu.00280.2006. (Pubitemid 44498426)
60. Kelly, M. L., Wang, M. J., Crisostomo, P. R., Abarbanell, A. M., Herrmann, J. L., Weil, B. R., et al. (2009). TNF recepter 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia. Shock, 33(6), 602-607. doi:10.1097/SHK.0b013e3181cc0913.
61. Bao, C. Y., Guo, J., Zheng, M., Chen, Y., Lin, G. S., & Hu, M. Y. (2010). Enhancement of the survival of engrafted mesenchymal stem cells in the ischemic heart by TNFR gene transfection. Biochemistry and Cell Biology, 88(4), 629-634. doi:10.1139/ 010-018.
62. Chang, S. A., Lee, E. J., Kang, H. J., Zhang, S. Y., Kim, J. H., Li, L., et al. (2008). Impact of myocardial infarct proteins and oscillating pressure on the differentiation of mesenchymal stem cells: Effect of acute myocardial infarction on stem cell differentiation. Stem Cells, 26(7), 1901-1912. doi:10.1634/stemcells.2007-0708.
63. Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., et al. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5(1), 54-63. doi:10.1016/j.stem.2009.05.003.
64. Nauta, A. J., & Fibbe, W. E. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood, 110(10), 3499-3506. doi:10.1182/blood-2007-02- 069716. (Pubitemid 350159613)
65. Meirelles, L. D., Fontes, A. M., Covas, D. T., & Caplan, A. I. (2009). Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine & Growth Factor Reviews, 20 (5-6), 419-427. doi:10.1016/j.cytogfr.2009.10.002.
66. Laterveer, L., Lindley, I. J. D., Hamilton, M. S., Willemze, R., & Fibbe, W. E. (1995). Interleukin-8 induces rapid mobilization of hematopoietic stem-cells with radioprotective capacity and longterm myelolymphoid repopulating ability. Blood, 85(8), 2269-2275.
67. Bocker, W. G., Docheva, D., Prall, W. C., Egea, V., Pappou, E., Rossmann, O., et al. (2008). IKK-2 is required for TNF-alphainduced invasion and proliferation of human mesenchymal stem cells. Journal of Molecular Medicine, 86(10), 1183-1192. doi:10.1007/s00109-008-0378-3.
68. Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D. H., Iwaguro, H., et al. (1999). VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J, 18(14), 3964-3972. (Pubitemid 29335849)
69. Tang, Y. L., Zhu, W. Q., Cheng, M., Chen, L. J., Zhang, J., Sun, T., et al. (2009). Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. CircRes, 104(10), 1209-U1218. doi:10.1161/circresaha.109.197723.
70. Nakamuta, J. S., Danoviz, M. E., Marques, F. L. N., dos Santos, L., Becker, C., Goncalves, G. A., et al. (2009). Cell therapy attenuates cardiac dysfunction post myocardial infarction: Effect of timing, routes of injection and a fibrin scaffold. PloS One, 4 (6), 10. doi:10.1371/journal.pone.0006005, e6005.
71. Barbash, I. M., Chouraqui, P., Baron, J., Feinberg, M. S., Etzion, S., Tessone, A., et al. (2003). Systemic delivery of bone marrowderived mesenchymal stem cells to the infarcted myocardium - Feasibility, cell migration, and body distribution. Circulation, 108(7), 863-868. doi:10.1161/01.cir.0000084828.50310. 6a. (Pubitemid 37022130)
72. Karp, J. M., & Teol, G. S. L. (2009). Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell, 4(3), 206-216. doi:10.1016/j.stem. 2009.02.001.
73. Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010). Stability of protein pharmaceuticals: An update. Pharmaceutical Research, 27(4), 544-575. doi:10.1007/ s11095-009-0045-6.
74. Davis,M. E., Hsieh, P. C. H., Grodzinsky, A. J.,& Lee, R. T. (2005). Custom design of the cardiac microenvironment with biomaterials. CircRes, 97(1), 8-15. doi:10.1161/01.res.0000173376.39447.01. (Pubitemid 40982317)
75. Ferreira, L., Pedroso, D. C., Vazão, H., & Gomes, R. S. (2010). Stem cell-based therapies for heart regeneration: What did the bench teach us? Cardiovascular & Hematological Disorders Drug Targets, 10(3), 173-185.
76. Freeman, I., & Cohen, S. (2009). The influence of the sequential delivery of angiogenic factors from affinity-binding alginate scaffolds on vascularization. Biomaterials, 30(11), 2122-2131. doi:10.1016/j.biomaterials. 2008.12.057.
77. Chen, F. M., Zhang, M., & Wu, Z. F. (2010). Toward delivery of multiple growth factors in tissue engineering. Biomaterials, 31 (24), 6279-6308. doi:10.1016/j.biomaterials.2010.04.053.
78. Mukherjee, S., Venugopal, J. R., Ravichandran, R., Ramakrishna, S., & Raghunath, M. (2010). Multimodal biomaterial strategies for regeneration of infarcted myocardium. Journal of Materials Chemistry, 20(40), 8819-8831. doi:10.1039/c0jm00805b.
79. Lindahl U, Li JP (2009) Interactions between heparan sulfate and proteins-design and functional implications. In: International Review of Cell and Molecular Biology, Vol 276, vol 276. International Review of Cell and Molecular Biology. Elsevier Academic Press Inc, San Diego, pp 105-159. doi:10.1016/ s1937-6448(09)76003-4
80. Kraehenbuehl, T. P., Ferreira, L. S., Zammaretti, P., Hubbell, J. A., & Langer, R. (2009). Cell-responsive hydrogel for encapsulation of vascular cells. Biomaterials, 30(26), 4318-4324. doi:10.1016/j.biomaterials.2009.04.057.
81. Vazao, H., das Neves, R. P., Graos, M., & Ferreira, L. (2011). Towards the maturation and characterization of smooth muscle cells derived from human embryonic stem cells. PloS One, 6(3), 14. doi:10.1371/journal.pone. 0017771.
82. Ferreira, L. S., Gerecht, S., Shieh, H. F., Watson, N., Rupnick, M. A.,Dallabrida, S. M., et al. (2007). Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle-like cells and form vascular networks in vivo. CircRes, 101(3), 286-294. doi:10.1161/circresaha.107.150201. (Pubitemid 47344078)
83. Kraehenbuehl, T. P., Zammaretti, P., Van der Vlies, A. J., Schoenmakers, R. G., Lutolf, M. P., Jaconi, M. E., et al. (2008). Three-dimensional extracellular matrix-directed cardioprogenitor differentiation: Systematic modulation of a synthetic cell-responsive PEG-hydrogel. Biomaterials, 29(18), 2757-2766. doi:10.1016/j.biomaterials.2008.03.016.
84. Sladek, T., Filkuka, J., Dolezel, S., Vasku, J., Hartmannova, B., & Travnickova, J. (1984). The border zone of the early myocardialinfarction in dogs - its characteristics and viability. Basic Research in Cardiology, 79(3), 344-349. doi:10.1007/BF01908035. (Pubitemid 14075526)
85. Sy, J. C., Seshadri, G., Yang, S. C., Brown, M., Oh, T., Dikalov, S., et al. (2008). Sustained release of a p38 inhibitor from noninflammatory microspheres inhibits cardiac dysfunction. Nature Materials, 7(11), 863-869. doi:10.1038/nmat2299.
86. Gupta, P., Vermani, K., & Garg, S. (2002). Hydrogels: From controlled release to pH-responsive drug delivery. Drug Discovery Today, 7(10), 569-579. doi:10.1016/S1359-6446(02)02255-9. (Pubitemid 34603648)
87. Qiu, Y., & Park, K. (2001). Environment-sensitive hydrogels for drug delivery. Advanced Drug Delivery Reviews, 53(3), 321-339. doi:10.1016/S0169- 409X(01)00203-4. (Pubitemid 34024913)
88. Lowman, A. M., Morishita, M., Kajita, M., Nagai, T., & Peppas, N. A. (1999). Oral delivery of insulin using pH-responsive complexation gels. Journal of Pharmaceutical Sciences, 88(9), 933-937. doi:10.1021/js980337n. (Pubitemid 29438959)
89. Miyata, T., Uragami, T., & Nakamae, K. (2002). Biomoleculesensitive hydrogels. Advanced Drug Delivery Reviews, 54(1), 79-98. doi:10.1016/S0169- 409X(01)00241-1. (Pubitemid 34075315)
90. Miyata, T., Asami, N., & Uragami, T. (1999). A reversibly antigen-responsive hydrogel. Nature, 399(6738), 766-769. doi:10.1038/21619. (Pubitemid 29293169)
91. Matsumoto, A., Yoshida, R., & Kataoka, K. (2004). Glucoseresponsive polymer gel bearing phenylborate derivative as a glucose-sensing moiety operating at the physiological pH. Biomacromolecules, 5(3), 1038-1045. doi:10.1021/bm0345413. (Pubitemid 38702281)
92. Wilson DS, Dalmasso G, Wang LX, Sitaraman SV, Merlin D, Murthy N Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 9 (11):923-928. doi:10.1038/ nmat2859
93. Broaders, K. E., Grandhe, S., & Frechet, J. M. J. (2011). A biocompatible oxidation-triggered carrier polymer with potential in therapeutics. Journal of the American Chemical Society, 133 (4), 756-758. doi:10.1021/ja110468v.
94. Lee, K. Y., Peters, M. C., Anderson, K. W., & Mooney, D. J. (2000). Controlled growth factor release from synthetic extracellular matrices. Nature, 408(6815), 998-1000. doi:10.1038/ 35050141. (Pubitemid 32101648)
95. Labhasetwar, V., Underwood, T., Schwendeman, S. P., & Levy, R. J. (1995). Iontophoresis for modulation of cardiac drug-delivery in dogs. Proceedings of the National Academy of Sciences of the United States of America, 92(7), 2612-2616.
96. Zhao, X. H., Kim, J., Cezar, C. A., Huebsch, N., Lee, K., Bouhadir, K., et al. (2010). Active scaffolds for on-demand drug and cell delivery. Proceedings of the National Academy of Sciences of the United States of America, 108(1), 67-72. doi:10.1073/pnas.1007862108.
97. Hausenloy, D. J., & Yellon, D. M. (2009). Cardioprotective growth factors. Cardiovascular Research, 83(2), 179-194. doi:10.1093/cvr/cvp062.
98. Kobayashi, H., Minatoguchi, S., Yasuda, S., Bao, N., Kawamura, I., Iwasa, M., et al. (2008). Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovascular Research, 79(4), 611-620. doi:10.1093/ cvr/cvn154.
99. Davis, M. E., Hsieh, P. C. H., Takahashi, T., Song, Q., Zhang, S. G., Kamm, R. D., et al. (2006). Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America, 103(21), 8155-8160. doi:10.1073/pnas. 0602877103. (Pubitemid 43801068)
100. Hao, X. J., Silva, E. A., Mansson-Broberg, A., Grinnemo, K. H., Siddiqui, A. J., Dellgren, G., et al. (2007). Angiogenic effects of sequential release of VEGF-A(165) and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovascular Research, 75(1), 178-185. doi:10.1016/j.cardiores.2007.03.028. (Pubitemid 46876668)
101. Formiga, F. R., Pelacho, B., Garbayo, E., Abizanda, G., Gavira, J. J., Simon-Yarza, T., et al. (2010). Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. Journal of Controlled Release, 147(1), 30-37. doi:10. 1016/j.jconrel.2010.07.097.
102. Seliktar, D., Zisch, A. H., Lutolf, M. P., Wrana, J. L., & Hubbell, J. A. (2004). MMP-2 sensitive, VEGF-bearing bioactive hydrogels for promotion of vascular healing. Journal of Biomedical Materials Research. Part A, 68A(4), 704-716. doi:10.1002/jbm. a.20091. (Pubitemid 38263935)
103. Silva, E. A., Kim, E. S., Kong, H. J., & Mooney, D. J. (2008). Material-based deployment enhances efficacy of endothelial progenitor cells. Proceedings of the National Academy of Sciences of the United States of America, 105(38), 14347-14352. doi:10.1073/pnas.0803873105.
104. Miyagi, Y., Chiu, L. L. Y., Cimini, M., Weisel, R. D., Radisic, M., & Li, R. K. (2010). Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Biomaterials, 32(5), 1280-1290. doi:10.1016/j. biomaterials.2010.10.007.
105. Segers, V. F. M., Tokunou, T., Higgins, L. J., MacGillivray, C., Gannon, J., & Lee, R. T. (2007). Local delivery of protease- resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation, 116(15), 1683-1692. doi:10.1161/circulationaha.107.718718. (Pubitemid 47537842)
106. Calvillo, L., Latini, R., Kajstura, J., Leri, A., Anversa, P., Ghezzi, P., et al. (2003). Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proceedings of the National Academy of Sciences of the United States of America, 100(8), 4802-4806. doi:10.1073/pnas.0630444100. (Pubitemid 36457809)
107. Wang, T., Jiang, X. J., Lin, T., Ren, S., Li, X. Y., Zhang, X. Z., et al. (2009). The inhibition of postinfarct ventricle remodeling without polycythaemia following local sustained intramyocardial delivery of erythropoietin within a supramolecular hydrogel. Biomaterials, 30(25), 4161-4167. doi:10.1016/j.biomaterials. 2009.04.033.
108. Ruvinov E, Leor J, Cohen S The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials 32 (2):565-578. doi:10.1016/j.biomaterials.2010. 08.097
109. Fraidenraich, D., Stillwell, E., Romero, E., Wilkes, D., Manova, K., Basson, C. T., et al. (2004). Rescue of cardiac defects in Id knockout embryos by injection of embryonic stem cells. Science, 306(5694), 247-252. (Pubitemid 39336864)
110. Tokunou, T., Miller, R., Patwari, P., Davis, M. E., Segers, V. F. M., Grodzinsky, A. J., et al. (2008). Engineering insulin-like growth factor-1 for local delivery. The FASEB Journal, 22(6), 1886-1893. doi:10.1096/fj.07-100925. (Pubitemid 351811465)
111. Ota, T., Gilbert, T. W., Schwartzman, D., McTiernan, C. F., Kitajima, T., Ito, Y., et al. (2008). A fusion protein of hepatocyte growth factor enhances reconstruction of myocardium in a cardiac patch derived from porcine urinary bladder matrix. The Journal of Thoracic and Cardiovascular Surgery, 136(5), 1309-1317. doi:10.1016/j.jtcvs.2008.07.008.
112. Cao, Y. H., Hong, A., Schulten, H., & Post, M. J. (2005). Update on therapeutic neovascularization. Cardiovascular Research, 65 (3), 639-648. doi:10.1016/j.cardiores.2004.11.020. (Pubitemid 40138984)
113. Sivakumar, B., Harry, L. E., & Paleolog, E. M. (2004). Modulating angiogenesis - More vs less. JAMA-J Am Med Assoc, 292(8), 972-977. doi:10.1001/jama.292.8.972. (Pubitemid 39097208)
114. Le, K., Hwang, C. W., Tzafriri, A. R., Lovich, M., & Edelman, E. (2008). Local therapeutic angiogenesis is limited by microvascular clearance. Circulation, 118(18), S457-S457.
115. Dor, Y., Djonov, V., & Keshet, E. (2003). Induction of vascular networks in adult organs: Implications to proangiogenic therapy. In M. NilsenHamilton, Z. Werb, & E. Keshet (Eds.), Tissue remodeling, vol 995. Annals of the New York Academy of Sciences (pp. 208-215). New York: New York Acad Sciences. (Pubitemid 36706628)
116. Dor, Y., Djonov, V., Abramovitch, R., Itin, A., Fishman, G. I., Carmeliet, P., et al. (2002). Conditional switching of VEGF provides new insights into adult neovascularization and proangiogenic therapy. Embo J, 21(8), 1939-1947. (Pubitemid 34437191)
117. Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., et al. (1999). Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science, 286(5449), 2511-2514. doi:10.1126/science.286. 5449.2511.
118. Hariawala, M. D., Horowitz, J. R., Esakof, D., Sheriff, D. D., Walter, D., Keyt, B., et al. (1996). VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res, 63(1), 77-82. doi:10.1006/jsre.1996.0226. (Pubitemid 26197723)
119. Ozawa, C. R., Banfi, A., Glazer, N. L., Thurston, G., Springer, M. L., Kraft, P. E., et al. (2004). Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. The Journal of Clinical Investigation, 113(4), 516-527. doi:10.1172/jci200418420. (Pubitemid 38542501)
120. Lee, R. J., Springer, M. L., Blanco-Bose, W. E., Shaw, R., Ursell, P. C., & Blau, H. M. (2000). VEGF gene delivery to myocardium - Deleterious effects of unregulated expression. Circulation, 102 (8), 898-901.
121. Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J., et al. (2003). Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation, 107(10), 1359-1365. doi:10.1161/01.cir. 0000061911.47710.8a. (Pubitemid 36350732)
122. Laham, R. J., Sellke, F.W., Edelman, E. R., Pearlman, J. D.,Ware, J. A., Brown, D. L., et al. (1999). Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery - Results of a phase I randomized, double-blind, placebocontrolled trial. Circulation, 100(18), 1865-1871. (Pubitemid 29511139)
123. Ruel, M., Laham, R. J., Parker, J. A., Post, M. J., Ware, J. A., Simons, M., et al. (2002). Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. The Journal of Thoracic and Cardiovascular Surgery, 124(1), 28-34. doi:10.1067/mtc.2002.121974.
124. Simons, M., Annex, B. H., Laham, R. J., Kleiman, N., Henry, T., Dauerman, H., et al. (2002). Pharmacological treatment of coronary artery disease with
125. Cao, R. H., Brakenhielm, E., Pawliuk, R., Wariaro, D., Post, M. J., Wahlberg, E., et al. (2003). Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nature Medicine, 9(5), 604-613. doi:10.1038/nm848. (Pubitemid 36597108)
126. Hsieh, P. C. H., Davis, M. E., Lisowski, L. K., & Lee, R. T. (2006). Endothelial-cardiomyocyte interactions in cardiac development and repair. Annual Review of Physiology, 68, 51-66. doi:10.1146/annurev.physiol.68.040104.124629.
127. Dvir, T., Kedem, A., Ruvinov, E., Levy, O., Freeman, I., Landa, N., et al. (2009). Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Proceedings of the National Academy of Sciences of the United States of America, 106(35), 14990-14995. doi:10.1073/pnas.0812242106.
128. McQuibban, G. A., Butler, G. S., Gong, J. H., Bendall, L., Power, C., Clark-Lewis, I., et al. (2001). Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem, 276(47), 43503-43508. doi:10.1074/jbc. M107736200.
129. Zaruba, M. M., Theiss, H. D., Vallaster, M., Mehl, U., Brunner, S., David, R., et al. (2009). Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell, 4(4), 313-323. doi:10.1016/j.stem.2009.02.013.
130. Penn, M. S. (2009). Importance of the SDF-1:CXCR4 axis in myocardial repair. CircRes, 104(10), 1133-1135. doi:10.1161/ circresaha.109.198929.
131. Petit, I., Szyper-Kravitz, M., Nagler, A., Lahav, M., Peled, A., Habler, L., et al. (2002). G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunology, 3(7), 687-694. doi:10.1038/ni813. (Pubitemid 34752479)
132. Landa, N., Miller, L., Feinberg, M. S., Holbova, R., Shachar, M., Freeman, I., et al. (2008). Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation, 117(11), 1388-1396. doi:10.1161/circulationaha. 107.727420. (Pubitemid 351506386)
133. Wall, S. T., Walker, J. C., Healy, K. E., Ratcliffe, M. B., & Guccione, J. M. (2006). Theoretical impact of the injection of material into the myocardium - A finite element model simulation. Circulation, 114(24), 2627-2635. doi:10.1161/circulationaha. 106.657270. (Pubitemid 44967346)
134. Nelson, D. M., Ma, Z. W., Fujimoto, K. L., Hashizume, R., & Wagner, W. R. (2010). Intra-myocardial biomaterial injection therapy in the treatment of heart failure: Materials, outcomes and challenges. Acta Biomaterialia, 7(1), 1-15. doi:10.1016/j.actbio. 2010.06.039.
135. Stastna, M., Chimenti, I., Marban, E., & Van Eyk, J. E. (2009). Identification and functionality of proteomes secreted by rat cardiac stem cells and neonatal cardiomyocytes. Proteomics, 10 (2), 245-253. doi:10.1002/pmic. 200900515.
136. Siwik, D. A., Chang, D. L. F., & Colucci, W. S. (2000). Interleukin-1 beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. CircRes, 86(12), 1259-1265. (Pubitemid 30436667)
137. Finkel, M. S., Hoffman, R. A., Shen, L., Oddis, C. V., Simmons, R. L., & Hattler, B. G. (1993). Interleukin-6 (IL-6) as a mediator of stunned myocardium. The American Journal of Cardiology, 71(13), 1231-1232. doi:10.1016/0002-9149(93)90654-U. (Pubitemid 23137577)
138. Kukielka, G. L., Smith, C. W., Manning, A. M., Youker, K. A., Michael, L. H., & Entman,M. L. (1995). Induction of interleukin-6 synthesis in the myocardium - potential role is postreperfusion inflammatory injury. Circulation, 92(7), 1866-1875.
139. Lacraz, S., Nicod, L. P., Chicheportiche, R., Welgus, H. G., & Dayer, J. M. (1995). IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. The Journal of Clinical Investigation, 96(5), 2304-2310. doi:10.1172/JCI118286.
140. Frangogiannis, N. G., Mendoza, L. H., Lindsey, M. L., Ballantyne, C. M., Michael, L. H., Smith, C. W., et al. (2000). IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol, 165(5), 2798-2808. (Pubitemid 30660731)
141. Sun, M., Dawood, F., Wen, W. H., Chen, M. Y., Dixon, I., Kirshenbaum, L. A., et al. (2004). Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation, 110(20), 3221-3228. doi:10.1161/01.cir.0000147233. 10318.23. (Pubitemid 39525069)
142. Yokoyama, T., Vaca, L., Rossen, R. D., Durante, W., Hazarika, P., & Mann, D. L. (1993). Cellular basis for the negative inotropic effects of tumor-necrosis-factor-alpha in the asult mammalian heart. The Journal of Clinical Investigation, 92(5), 2303-2312. doi:10.1172/JCI116834. (Pubitemid 23333536)
143. Frangogiannis, N. G., Lindsey, M. L., Michael, L. H., Youker, K. A., Bressler, R. B., Mendoza, L. H., et al. (1998). Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation, 98(7), 699-710. (Pubitemid 28387497)